Immunotherapy designed to expand cytotoxic T lymphocytes (CTLs) that recognize Major Histocompatibility Class I molecule (MHCI)-presented tumor antigens on tumor cells, including survivin, have shown encouraging results in small clinical trials [6,7,8,9]. This evidence concerns the gene BIRC5 and neoplasm.